Merck/Schering-Plough's combination therapy ezetimibe/simvastatin [`Zetia/Zocor'] for the treatment of hyperlipidaemia is unlikely to be added to the formulary of many US HMOs,

Source: PharmacoEconomics and Outcomes News, Volume 1, Number 417, 2003 , pp. 7-7(1)

Keywords: Ezetimibe, therapeutic use; Formularies; Health-maintenance-organisations; Healthcare-news; Lipid-metabolism-disorders, treatment; Rosuvastatin, therapeutic use

Document Type: Short communication

Links for this article

http://www.ingentaconnect.com/adis/peon/2003/00000001/00000417/art00015
http://openurl.ingenta.com/content?genre=article&issn=1173-5503&volume=1&issue=417&spage=7&epage=7
http://dx.doi.org/NO_DOI